

Data Sheet

Plasmid #22

SKU No.: 02-1022

Description	Plasmid #22 enables the tagging of target proteins with a cleavable CL7 at the N-terminus and an uncleavable His8 at the C-terminus. There are three options for the 5' placement of target genes, and SpeI is the 3' cloning site.
Expression	Transcription is induced with IPTG and driven by the T7 RNA polymerase. The plasmid is designed for expression in E. Coli.
Affinity Tag	The N-terminus of the protein is tagged with CL7.
Cleavage Site(s)	Plasmid #21 contains two PreScission protease (PSC) cleavage sites between the CL7 and His8 tags. Downstream of the His8 tag are SUMO and Sortase A cleavage sites.
Other Tags	The coding region begins with a Trx tag and ends with a His8 tag in Plasmid #22.
Resistance	Kanamycin
Form	100 ng, dissolved in water.
Concentration	30 ng/μL
Stability	12 months after shipping
Storage	-20° C
Shipping	Room temperature

Scheme

1. HindIII/SpeI Insertion Site – Trx | CL7 | 20-Amino Acid Linker | SUMO | SRT | 13-Amino Acid Linker | Gene of Interest | His8
2. KpnI/SpeI Insertion Site – Trx | CL7 | 20-Amino Acid Linker | SUMO | 3| Gene of Interest | His8
3. Bsu36I/SpeI Insertion Site – Trx | CL7 | 20-Amino Acid Linker | SUMO | Gene of Interest | His8

The Bsu36I/SpeI insertion scheme maintains the Gene of Interest's wildtype sequence, without adding any extra residues. The N-terminus of the Gene of Interest must include the following to complete the SUMO C-terminal sequence:

P E D L D M E D N D I I E A H R E Q I G G
 CCTGAGGATCTGGACATGGAAGACAATGACATTATCGAAGCTCATCGTGAACAGATTGGTGGT<Gene of Interest>
 Bsu36I

You can download the full protocol from <https://trialtusbioscience.com/products/#protocols>.

**For research use only.
Not for diagnostic or therapeutic use.**

Licensing Information

TriAltus Bioscience holds the exclusive, worldwide license to the CL7 protein purification technology platform. It was licensed from the University of Alabama at Birmingham (UAB) in Birmingham, Alabama, USA. An international patent filing has been made with protection being sought in the United States, Europe, and other major markets. The CL7 purification technology is available for research use. For commercial use or resale, contact us at sales@trialtusbioscience.com to discuss commercial licensing.

Trademarks

The Company name, the terms "TriAltus" and "TriAltus Bioscience", the Company logo, and all related names, logos, product and service names, designs, and slogans are trademarks of the Company or its affiliates or licensors. You must not use such marks without the prior written permission of the Company. All other names, logos, product and service names, designs, and slogans on this Website are the trademarks of their respective owners.

Version: 1.0
Revision Date: 11/20/2019